点评研究

Abstract #: S180

DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB， THALIDOMIDE， AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS

新诊断多发性骨髓瘤患者使用硼替佐米、沙利度胺和地塞米松（D-VTd）±自体干细胞移植(ASCT)治疗后使用达雷木单抗维持治疗vs观察：CASSIOPEIA试验第2部分结果

Abstract #: S181

DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL

DARA-CVRD和强化的自体移植治疗超高危骨髓瘤和浆细胞白血病的深层次的反应和MRD状态：基于危险分层的英国OPTIMUM/MUKNINE试验结果

Abstract #: S184

MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4

新诊断多发性骨髓瘤患者在伊沙佐米 (IXA)维持期间的MRD评估:对1280名纳入TOURMALINE-MM3 和 -MM4试验患者的大型分析

?

点评研究

Abstract #: S145

FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

阿卡拉布鲁替尼与伊布替尼治疗慢性淋巴细胞白血病的头对头试验的初步结果

Abstract #: S146

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

VENETOCLAX-OBINUTUZUMAB初始治疗慢性淋巴细胞白血病：随机CLL14研究的4年随访分析

Abstract #: S149

MRD-GUIDED OR FIXED 12 CYCLES OF VENETOCLAX CONSOLIDATION AFTER VENETOCLAX PLUS OBINUTUZUMAB TREATMENT IN FIRST-LINE FCR UNFIT PATIENTS WITH CLL: PRIMARY ENDPOINT ANALYSIS OF THE HOVON 139/GIVE TRIAL

MRD引导或固定12个疗程的VENETOCLAX联合OBINUTUZUMAB治疗一线FCR不适合的CLL患者：HOVON 139/GIVE试验的主要终点分析

点评研究

Abstract #:S131

SURVIVAL OUTCOMES FROM THE QUAZAR AML-001 TRIAL WITH ORAL AZACITIDINE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA IN REMISSION BY DISEASE SUBTYPE， CYTOGENETIC RISK， AND NPM1 MUTATION STATUS AT DIAGNOSIS

QUAZAR AML-001临床试验生存结果：口服阿扎胞苷治疗已达到缓解的不同亚组AML患者（根据疾病亚型、细胞遗传学风险和诊断时NPM1突变状态）

Abstract #:S135

EFFICACY AND SAFETY OF VENETOCLAX IN COMBINATION WITH GILTERITINIB FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: UPDATED ANALYSES OF A PHASE 1B STUDY

维奈克拉联合吉瑞替尼治疗复发/难治FLT3突变急性髓系白血病的有效性和安全性评价:一项1b期研究的最新分析

Abstract #:S128

STANDARDIZING NGS-MRD IN AML: AN INTERNATIONAL STUDY BY THE ELN-MRD WORKING PARTY

规范AML患者NGS-MRD检测标准：一项由ELN-MRD 工作组开展的国际性研究

点评研究

Abstract #:S112

UPDATED RESULTS OF THE GIMEMA LAL2116， D-ALBA TRIAL， FOR NEWLY DIAGNOSED ADULTS WITH PH+ ALL

Dasatinib联合Blinatumomab 用于成人初治 Ph+ ALL 患者的一线治疗：GIMEMA LAL2116 D-ALBA试验的更新结果

Abstract #:S113

INTERIM RESULTS OF A PHASE II STUDY OF BLINATUMOMAB PLUS PONATINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

一项关于Blinatumomab联合Ponatinib用于费城染色体阳性的急性淋巴细胞白血病的II期临床试验的中期结果

Abstract #:S114

PRELIMINARY RESULTS OF THE GIMEMA LAL2317 SEQUENTIAL CHEMOTHERAPY-BLINATUMOMAB FRONT-LINE TRIAL FOR NEWLY DIAGNOSED ADULT PH-NEGATIVE B-LINEAGE ALL PATIENTS

GIMEMA LAL2317：化疗序贯Blinatumomab用于成人初治PH阴性 B 淋巴细胞白血病一线治疗的初步结果?